<DOC>
	<DOCNO>NCT02344992</DOCNO>
	<brief_summary>The addition BioChaperone already market prandial insulin analogue accelerate onset shorten duration action insulin lispro due facilitation absorption insulin subcutaneous injection . This trial intented compare post-prandial blood glucose control BioChaperone insulin lispro Humalog® inject standardized meal well pharmacokinetic profile BioChaperone insulin lispro Humalog® subject type 1 diabetes mellitus . This double-blinded , randomize , control , two-period crossover phase Ib trial compare blood glucose control ingestion standardize meal , BioChaperone Lispro 0.2U/Kg Humalog 0.2U/Kg .</brief_summary>
	<brief_title>Blood Glucose Control With BioChaperone Insulin Lispro Compared Insulin Lispro ( Humalog® ) After Ingestion Standardized Meal</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Type 1 Diabetes Mellitus ≥ 12 month Treated multiple daily insulin injection CSII ≥ 12 month BMI 18.528.0 kg/m² ( inclusive ) HbA1C % ≤9 % Type 2 Diabetes Mellitus Receipt trial product within 60 day prior trial Clinically significant abnormal haematology , biochemistry , lipids urinalysis screen test judge investigator consider underlying disease Presence clinically significant acute gastroinstestinal symptom judge investigator Known slow gastric empty gastrointestinal surgery opinion investigator might change gastrointestinal motility food absorption . Any systemic treatment drug know interfere glucose metabolism Use tobacco nicotinecontained product within one year prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>